Search

everythinglearnresearchcommunity

for

Search:↓

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

User experienced hair regrowth using Min, Fin, RU, micro needling, and keto. Others encouraged consistency and shared excitement for future progress.

Minoxidil may cause skin aging effects like wrinkles and dark circles, but evidence is mixed. Alternatives like dermarolling and retinol are suggested.

A user found out they are vitamin D deficient and was prescribed high-dose vitamin D supplements, asking if others had similar experiences and if it improved their hair. Some shared improved mood and testosterone levels after treatment, while another combined vitamin D supplements with finasteride due to family history of baldness.

A 21-year-old experienced erectile dysfunction after using finasteride and consuming multiple drugs, including MDMA, LSD, and weed. He plans to quit finasteride and weed, improve his habits, and consider alternative treatments like mesotherapy with dutasteride.

The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.

A user experienced severe side effects, including symptoms of congestive heart failure, after using excessive doses of minoxidil for beard growth. They stopped using it due to financial reasons, but still suffer from lingering symptoms and are advised to seek medical attention.

A user discusses dealing with lower libido caused by finasteride, considering using ED meds but unsure due to age. Replies suggest natural libido fluctuations, holistic approaches, and managing anxiety.

A user's success in treating his diffuse and crown hair loss with finasteride and minoxidil; other users sharing their experiences, both successful and unsuccessful, and the importance of research and listening to one's body when deciding on treatments.

A 33-year-old male shared his hair regrowth journey, using minoxidil, dermarolling, hair brushing, scalp oils, dietary changes, and supplements. After five months, he started finasteride to improve hair thickness.

Tretinoin's effect on hair loss is debated; some say it improves minoxidil's effectiveness, while others claim it causes hair loss. Treatments discussed include tretinoin, minoxidil, finasteride, RU58841, and dermarolling.

A user's experience with finasteride to prevent hair loss, and how minoxidil may also have played a role in the successful results.

Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hair growth.

A user's 12 month progress on finasteride and 10 months of microneedling for hair loss treatment, which has resulted in improved temple areas with no side effects from the finasteride. They have not used minoxidil yet but are considering it for further gains. DHT blocking drugs such as finasteride and dutasteride are recommended to maintain regrowth results.

Finasteride effectively stopped hair loss for five years without side effects but led to complacency in life. Young men are advised to consider it for hair loss but not to take it for granted.

A user shared their 2-month results using Minoxidil 5%, dermarolling, ketoconazole shampoo, and castor oil for hair loss. They stopped using finasteride due to side effects.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

Concerns about the effectiveness of DHT inhibitors like finasteride and minoxidil due to potential polymorph issues. Experts suggest these concerns are largely unfounded, especially compared to rare cases like ritonavir.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses using B6 and Zinc to inhibit 5ar activity, similar to Fin and Dut. Minoxidil is mentioned as a supplementary treatment.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Pyrilutamide's systemic degradation is unclear, unlike fluridil, which becomes inactive in the body. The discussion focuses on whether pyrilutamide shares this property.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.